Clyde Biosciences has taken more than 100 years of experience in cardiac science to develop CellOPTIQ®, its unique combination of leading science and innovation.
A leap forward in assessing cardiac toxicity, CellOPTIQ® provides patch-clamp quality data in a medium throughput format. Using standard 96 well plates and modern voltage sensitive optical sensors, CellOPTIQ® answers research questions more swiftly and more thoroughly than any other system.
The Power of 3
Clyde’s Power of 3 combines the three cardinal measurements in cardiac safety assessments. By measuring voltage, calcium and contraction in one experiment Clyde’s clients enjoy remarkable precision in their acquisition of data.
Replace multi-electrode array, calcium transient and impedance assays with Clyde's Power of 3.
Power of 3 – Outputs
Mixed Ion Channel Effects
The Power of 3 on CellOPTIQ is able to show mixed ion channel effects. In this example, Nifedipine and E4031 combined to show mixed Ion channel effects:
Mixed ion channel blockade was mimicked by the co-administration of E-4031 (hERG blocker) and Nifedipine (Ca2+ channel blocker). At a critical combined concentrations of both drugs 30nM E4031 + 30nM Nifedipine (red), APD properties were not significantly different from baseline whereas [Ca2+]i was markedly reduced due to underlying L-type Ca2+ channel inhibition. Panels C and D show example AP and Calcium transient traces, respectively, for baseline (black traces) and combined Nifedipine and E4031 treatment 0.03 μM of each drug (red traces). This highlights the importance of measuring more than one parameter when compounds have mixed ion channel effects.
Comparison of CellOPTIQ to Other Assay Types
- Cycle Length
- APD 10-90
- Diastolic Interval
- EAD classification
- Mode of Toxicity
- Beat Rate
- CaT Rise Time
- CaT Decay Time
- Diastolic/systolic ratio
- Rise Time of Contraction
- Contraction Duration at 50% amplitude
- Contraction Duration at 90% amplitude
- Contraction Amplitude
“I would do a voltage sensitive dye study on the myocyte” – Major Pharma, Global Head of Safety
“A reasonable approach” – FDA Physician